TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25440004

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Second-generation supraglottic airway devices (SADs)
Number of subjects: 117

Group type: COMPARATOR
Intervention: First-generation SAD
Number of subjects: 117

Group type: COMPARATOR
Intervention: Laryngeal mask airway unique
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction disposable
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask airway (SLMA)
Number of subjects: 117
Study: 22137378

Group type: EXPERIMENTAL
Intervention: Adequate therapy (AT) with meropenem or meropenem plus ciprofloxacin
Number of subjects: 739

Group type: COMPARATOR
Intervention: Inadequate therapy (IT)
Number of subjects: 739
Study: 20147300

Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RMS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Custom Spectacles (CS)
Number of subjects: 400
Study: 18589019

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with free virgin olive oil (1 L/week)
Number of subjects: 1551

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with free mixed nuts (30 g/day)
Number of subjects: 1551

Group type: COMPARATOR
Intervention: Control group (verbal instructions and leaflet recommending National Cholesterol Education Program Adult Treatment Panel III dietary guidelines)
Number of subjects: 1551
Study: 15802772

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, MK‐4) 45 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, MK‐4)
Number of subjects: 0
Study: 12575213

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg once daily intravenous drip)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice daily intravenous drip)
Number of subjects: 119
Study: 14528551

Group type: EXPERIMENTAL
Intervention: Verbal and written information provided prior to the PHE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Verbal and written information provided following the second interview
Number of subjects: 100
Study: 8599587

Group type: EXPERIMENTAL
Intervention: Baking soda-hydrogen peroxide dentifrice (Mentadent)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo dentifrice (Crest)
Number of subjects: 25
Study: 31912800

Group type: EXPERIMENTAL
Intervention: Istiratumab (2.8 g intravenously every 2 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nab-paclitaxel and gemcitabine (control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall population (both arms)
Number of subjects: 88
Study: 30894210

Group type: EXPERIMENTAL
Intervention: HF-LED-RL phototherapy at doses of 480 J/cm2 and 640 J/cm2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mock therapy
Number of subjects: 60
Study: 27760887

Group type: EXPERIMENTAL
Intervention: iRest® meditation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dreampad Pillow®
Number of subjects: 29

Group type: COMPARATOR
Intervention: sleep hygiene
Number of subjects: 29
Study: 25348834

Group type: EXPERIMENTAL
Intervention: Ultrasound guided group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 23673688

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Electronic calculator
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pen and paper
Number of subjects: 36
Study: 22094316

Group type: EXPERIMENTAL
Intervention: Rapid rehydration (60 mL/kg) with 0.9% saline over an hour
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard rehydration (20 mL/kg) with 0.9% saline over an hour
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Rapid rehydration
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard rehydration
Number of subjects: 226
Study: 19015353

Group type: EXPERIMENTAL
Intervention: 20 mg of elvucitabine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 300 mg of ritonavir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg of elvucitabine coadministered with 300 mg of ritonavir
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 16886929

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA) patients
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Migraine without aura (MoA) patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: Young stroke patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: Elderly stroke patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: Cryptogenic stroke in young patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: Cryptogenic stroke in elderly patients
Number of subjects: 471
Study: 14984149

Group type: EXPERIMENTAL
Intervention: DFDBA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 39
Study: 14728013

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 9413102

Group type: EXPERIMENTAL
Intervention: Td + full strength acellular pertussis vaccine (PT, 1 microgram/0.5 ml; FHA, 4 micrograms/0.5 ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Td + half strength acellular pertussis vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Td alone
Number of subjects: 80
Study: 8480701

Group type: EXPERIMENTAL
Intervention: rhGH therapy (experimental group, n = 18)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 29
Study: 3119959

Group type: EXPERIMENTAL
Intervention: LHRH (25 micrograms)
Number of subjects: 25

Group type: COMPARATOR
Intervention: TRH (200 micrograms)
Number of subjects: 25
Study: 31109255

Group type: EXPERIMENTAL
Intervention: Healthy Body Image Program (online platform for screening and delivering tailored feedback and interventions)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Referral for treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Reasons for seeking treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Barriers to treatment
Number of subjects: 61
Study: 31666270

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg initially, followed by 7.5 mg/kg every 6 hours for 5 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous 5% dextrose (every 6 hours for 5 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 100
Study: 29171485

Group type: EXPERIMENTAL
Intervention: Cytoflavin (2nd group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intraoperative metabolic‐mediated cerebroprotection (1st group)
Number of subjects: 60
Study: 26619943

Group type: EXPERIMENTAL
Intervention: Supplementary food given to underweight children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets targeted to undernutritioned children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline bed net coverage at 20%
Number of subjects: 0
Study: 23942975

Group type: EXPERIMENTAL
Intervention: Soft contact lens with chiseled edge design
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soft contact lens with knife edge design
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soft contact lens with plano midperipheral shape profile
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soft contact lens with different edge designs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soft contact lens with midperipheral shape profile
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soft contact lens with edge design
Number of subjects: 26
Study: 22216653

Group type: EXPERIMENTAL
Intervention: Test Dentifrice 1 (0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% sodium fluoride, specially-designed silica)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Test Dentifrice 2 (0.454% stannous fluoride, sodium hexametaphosphate, zinc lactate)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride)
Number of subjects: 118
Study: 19798634

Group type: EXPERIMENTAL
Intervention: Immediate release acipimox capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium salt form of acipimox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free acid form of acipimox
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration to the colon
Number of subjects: 0
Study: 16820995

Group type: EXPERIMENTAL
Intervention: Ambroxol (45 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbocisteine (1500 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Rebamipide (300 mg/day)
Number of subjects: 54
Study: 12631533

Group type: EXPERIMENTAL
Intervention: Bilateral-redundant stimulus pairs (Go-Both Task)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Redundant target stimuli (Go/No-Go Task)
Number of subjects: 20
Study: 10853205

Group type: EXPERIMENTAL
Intervention: Manual lung hyperinflation treatment (patient positioning, suctioning, and manual lung hyperinflation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Manual lung hyperinflation treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Side-lying treatment (patient positioning and suctioning)
Number of subjects: 18
Study: 9489064

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate plus calcium supplementation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Continuous calcium supplementation
Number of subjects: 55
Study: 8096526

Group type: EXPERIMENTAL
Intervention: Gepirone 2 mg/day increasing to 12 mg/day over 3 weeks
Number of subjects: 21
Study: 2869057

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29934799

Group type: EXPERIMENTAL
Intervention: Black patient with a decayed tooth
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Black patient with an ill-adapted amalgam
Number of subjects: 636
Study: 29717839

Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) (6g, tid) for 3 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral Testosterone Undecanoate Capsules (TUC) (80 mg, qd) for 3 months
Number of subjects: 63
Study: 25788231

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard treatment (including balloon aortic valvuloplasty)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 358
Study: 23733499

Group type: EXPERIMENTAL
Intervention: Laser therapy (10 W class IV laser, 6.6 ± 1.3 J/cm²)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study: 22117974

Group type: COMPARATOR
Intervention: Molecular target therapy gefitinib (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryoablation prior to gefitinib (group II)
Number of subjects: 36
Study: 19448045

Group type: EXPERIMENTAL
Intervention: Formula 1 (isomaltulose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formula 2 (sucromalt)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fat formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 15
Study: 16786395

Group type: EXPERIMENTAL
Intervention: Statistical model for non-invasive estimation of AAA wall strength distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backwards-stepwise regression and linear mixed-effects modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demonstrative application of the model
Number of subjects: 0
Study: 15325921

Group type: EXPERIMENTAL
Intervention: Alteplase and lanoteplase (thrombolytic therapy)
Number of subjects: 147
Study: 11230478

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus radiotherapy (CT/RT group)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT group)
Number of subjects: 456
Study: 9436408

Group type: EXPERIMENTAL
Intervention: Low-dose levodopa therapy (0.5 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 8056007

Group type: EXPERIMENTAL
Intervention: Ridogrel 300 mg i.v. before thrombolytic treatment and 300 mg b.i.d. orally thereafter
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous ASA 250 mg immediately before thrombolytic treatment and 100 mg once a day orally thereafter
Number of subjects: 90
Study: 2691819

Group type: EXPERIMENTAL
Intervention: Upright cycle ergometry (UP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Semi-recumbent cycle ergometry (SR)
Number of subjects: 20
Study: 4581080

Group type: EXPERIMENTAL
Intervention: Slow Sodium (sodium chloride preparation)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30586365

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 267
Study: 27586506

Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprorelin acetate or goserelin acetate)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (degarelix)
Number of subjects: 56
Study: 24214840

Group type: EXPERIMENTAL
Intervention: CDC gynecologic cancer education materials
Number of subjects: 1380
Study: 23867113

Group type: EXPERIMENTAL
Intervention: Parecoxib plus opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioids alone
Number of subjects: 0
Study: 20439798

Group type: EXPERIMENTAL
Intervention: Identification-only intervention
Number of subjects: 487

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: All interventions (educational intervention, identification, both, or no intervention)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: High baseline hyperactivity/inattention scores (regardless of intervention)
Number of subjects: 487
Study: 19025397

Group type: EXPERIMENTAL
Intervention: Virological arm (VA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Immunological arm (IA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 121
Study: 16523265

Group type: EXPERIMENTAL
Intervention: Acupuncture and acupressure at point P6
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham point treatment
Number of subjects: 28
Study: 14719754

Group type: EXPERIMENTAL
Intervention: Packable resin‐based composite (SureFil)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Conventional hybrid resin‐based composite (SpectrumTPH)
Number of subjects: 65
Study: 11063446

Group type: EXPERIMENTAL
Intervention: Improved iodine status (increased urinary iodine concentrations)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Unchanged iodine status (no increase in urinary iodine concentrations)
Number of subjects: 196
Study: 8930778

Group type: EXPERIMENTAL
Intervention: Clemastine solution (1, 2, and 4 mg)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Clemastine tablets (1 mg and 2 mg)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Coadministration of clemastine with phenylpropanolamine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combination tablets (1 mg or 2 mg clemastine + 75 mg phenylpropanolamine)
Number of subjects: 171
Study: 1409882

Group type: EXPERIMENTAL
Intervention: Concentric isokinetic contractions at velocities of 30, 90, 120, and 180 degrees/s; Eccentric isokinetic contractions at velocities of 30, 90, 120, and 180 degrees/s; Isometric contractions at 40 and 60 degrees of knee flexion.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Practice protocol developed from initial testing.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Test and retest sessions.
Number of subjects: 10
Study: 3907919

Group type: EXPERIMENTAL
Intervention: Tobramycin plus ticarcillin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Netilmicin plus ticarcillin
Number of subjects: 98
Study: 31194897

Group type: EXPERIMENTAL
Intervention: HEV RNA positive samples
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: HEV IgM positive samples
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: HEV IgG positive samples
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: Indirect evidence of recent HEV exposure
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: HEV IgG positive samples in randomly selected samples
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: Overall prevalence of active HEV infection
Number of subjects: 38137

Group type: EXPERIMENTAL
Intervention: Anti-HEV IgG prevalence
Number of subjects: 38137
Study: 29288581

Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All needle sizes in hyperechoic nodules
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All needle sizes in hypoechoic nodules
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Nodule size
Number of subjects: 156
Study: 26863885

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 14
Study: 25354951

Group type: EXPERIMENTAL
Intervention: Home-based training (HT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Centre-based training (CT)
Number of subjects: 50
Study: 23006787

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No Kinesio taping (Control)
Number of subjects: 18
Study: 19821225

Group type: EXPERIMENTAL
Intervention: High protein diet (PROT) - 30% protein content, 16.74 MJ
Number of subjects: 10

Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO) - 68% carbohydrate, 16.74 MJ
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High protein diet (PROT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO)
Number of subjects: 10
Study: 19130860

Group type: EXPERIMENTAL
Intervention: Yoga training for six weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no yoga training)
Number of subjects: 46
Study: 15990196

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a (40 KD)/ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1121
Study: 12943875

Group type: EXPERIMENTAL
Intervention: Metoprolol or carvedilol for 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (12 age-matched healthy volunteers)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 33
Study: 10789958

Group type: EXPERIMENTAL
Intervention: Octreotide 0.3 mg daily (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hyoscine butylbromide (HB) 60 mg daily (n = 9)
Number of subjects: 18
Study: 8872652

Group type: EXPERIMENTAL
Intervention: Endurance exercise with thermal clamp (39 degrees C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Endurance exercise without thermal clamp (23 degrees C)
Number of subjects: 9
Study: 1524042

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiotherapy (Group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (A and B) with complete response
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group A (Radiotherapy)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group B (Induction chemotherapy followed by radiotherapy)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen
Number of subjects: 42
Study: 3542496

Group type: EXPERIMENTAL
Intervention: Colchicine therapy (4 X 0.25 mg/d for five days a week)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: COMPARATOR
Intervention: Colchicine therapy and Placebo
Number of subjects: 74
Study: 29902037

Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention for depression
Number of subjects: 71
Study: 25746819

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified milk beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfortified milk based control drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 24935757

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 121
Study: 22234594

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training simulator for hysteroscopic placement of tubal sterilization implants
Number of subjects: 46
Study: 19117959

Group type: EXPERIMENTAL
Intervention: 30 U/kg unfractionated heparin bolus
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0 U/kg unfractionated heparin bolus
Number of subjects: 54

Group type: COMPARATOR
Intervention: 80 U/kg unfractionated heparin bolus
Number of subjects: 54
Study: 23756099

Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) guided personalized embryo transfer (pET)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) after ERA
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) after second ERA
Number of subjects: 110
Study: 16416345

Group type: EXPERIMENTAL
Intervention: Patients with aMCI
Number of subjects: 107

Group type: COMPARATOR
Intervention: Patients reporting memory problems without memory deficit
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall patients reporting memory decline
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 107

Group type: COMPARATOR
Intervention: Patients with aMCI compared to patients without evident memory impairment
Number of subjects: 107
Study: 12858654

Group type: EXPERIMENTAL
Intervention: OCM (omeprazole + clarithromycin + metronidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCM (ranitidine + clarithromycin + metronidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OAM (omeprazole + amoxicillin + metronidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAM (ranitidine + amoxicillin + metronidazole)
Number of subjects: 0